 Oncorus Inc NASDAQ: ONCR has signed an exclusive licensing agreement with Gaeta Therapeutics Ltd, related to the use of locally delivered Interleukin-12 IL-12 via oncolytic viral expression in combination with an immune checkpoint inhibitor. IL-12 is one of five immunomodulatory payloads in Oncorus lead viral immunotherapy product candidate, ONCR-177. 